TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19095138

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate 200 mg/day
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 16213291

Group type: EXPERIMENTAL
Intervention: Peak cyclosporine blood levels guided by calculating the area under the curve
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cyclosporine trough levels
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Peak cyclosporine blood levels
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Calculated area under the curve
Number of subjects: 65

Group type: COMPARATOR
Intervention: Incidence of acute rejection, cyclosporine nephrotoxicity, proteinuria, serum creatinine levels, graft and patient outcomes
Number of subjects: 65
Study: 11843722

Group type: EXPERIMENTAL
Intervention: 5 mL of 0.5% bupivacaine hydrochloride
Number of subjects: 63

Group type: COMPARATOR
Intervention: 5 mL of isotonic sodium chloride solution (Control)
Number of subjects: 63
Study: 10443523

Group type: EXPERIMENTAL
Intervention: Dissection and suture of the serratus anterior muscle
Number of subjects: 28

Group type: COMPARATOR
Intervention: Preservation of the serratus anterior muscle
Number of subjects: 28
Study: 8847270

Group type: EXPERIMENTAL
Intervention: High intensity exercise (70% maximal oxygen consumption x 50 min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low intensity exercise (40% maximal oxygen consumption x 87 min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 24
Study: 2161328

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 380614

Group type: EXPERIMENTAL
Intervention: Clofibrate (2 g/day; period B; 2 months)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (periods A and C, 2 months each)
Number of subjects: 22
Study: 6210878

Group type: EXPERIMENTAL
Intervention: Cl2MDP (3200 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30690293

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (doxorubicin plus ifosfamide)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 290
Study: 30267999

Group type: EXPERIMENTAL
Intervention: FilmArray Respiratory Panel (FilmArray-RP)
Number of subjects: 432
Study: 26574195

Group type: EXPERIMENTAL
Intervention: Motivational interview with significant other (SO)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Motivational interview without significant other
Number of subjects: 406
Study: 24985959

Group type: EXPERIMENTAL
Intervention: Ambient orange fragrance
Number of subjects: 56

Group type: COMPARATOR
Intervention: No fragrance (control)
Number of subjects: 56
Study: 21900227

Group type: EXPERIMENTAL
Intervention: Good-quality peripapillary circular OCT scans (global signal strength (SS) ≥ 6); fast retinal nerve fibre layer scan protocol; Stratus OCT.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Global mean QI, QI SD, and their interaction term in logistic mixed-effects regression modeling.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Mean QI < 20 or SS < 8.
Number of subjects: 68
Study: 20619854

Group type: EXPERIMENTAL
Intervention: Conventional ventilation (85% of patients)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Newer conventional ventilation modes (volume targeted and pressure support)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Positive end‐expiratory pressure (PEEP)
Number of subjects: 535
Study: 17611916

Group type: EXPERIMENTAL
Intervention: 3 L of polyethylene glycol solution with a soft diet on the preceding day and then 1 L of the solution on the day of colonoscopy (split-dose)
Number of subjects: 303

Group type: COMPARATOR
Intervention: 4 L of polyethylene glycol solution with a soft diet on the day before colonoscopy (single-dose)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Good compliance (116 in group A, 119 in group B)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Poor compliance (36 in group A, 32 in group B)
Number of subjects: 303
Study: 16083526

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus Fluvastatin 20 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12394229

Group type: EXPERIMENTAL
Intervention: Mannitol infusion (100‐mL 20% mannitol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5% dextrose solution (control group)
Number of subjects: 30
Study: 10825856

Group type: EXPERIMENTAL
Intervention: Colgate Tartar Control Plus Whitening Fluoride Toothpaste
Number of subjects: 58

Group type: COMPARATOR
Intervention: Crest Tartar Control Toothpaste
Number of subjects: 58
Study: 7581431

Group type: EXPERIMENTAL
Intervention: intensive training of muscle endurance
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: muscle training including coordination
Number of subjects: 40
Study: 2310448

Group type: EXPERIMENTAL
Intervention: Intraarticular injection of bupivacaine (100 mg, 40 mL of 0.25%)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Intraarticular injection of saline
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of bupivacaine at the portal sites
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both intraarticular and subcutaneous injection of bupivacaine
Number of subjects: 101
Study: 393441

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Surgical excision only
Number of subjects: 18
Study: 29553309

Group type: EXPERIMENTAL
Intervention: Botulinum toxin‐A plus evidence‐based movement training
Number of subjects: 136

Group type: COMPARATOR
Intervention: Botulinum toxin‐A alone
Number of subjects: 136
Study: 29194242

Group type: EXPERIMENTAL
Intervention: Experiential teaching strategy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 78
Study: 26284906

Group type: EXPERIMENTAL
Intervention: C. militaris (1.5 g/day for 4 weeks)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (identical capsules filled with microcrystalline cellulose and lactose)
Number of subjects: 79
Study: 23118143

Group type: EXPERIMENTAL
Intervention: Tailored Navigation Intervention (TNI) Group
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Standard Intervention (SI) Group
Number of subjects: 945

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 945
Study: 21969008

Group type: EXPERIMENTAL
Intervention: Salmonella typhi vaccine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cytokines (interleukin‐6/tumor necrosis factor‐α/lipopolysaccharide)
Number of subjects: 20

Group type: COMPARATOR
Intervention: GCH1 X haplotype (XX)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GCH1 OO haplotype (OO)
Number of subjects: 20
Study: 18223378

Group type: EXPERIMENTAL
Intervention: Standard infant formula supplemented with IGF‐1 (10 microg/100 mL of formula)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 60
Study: 16611656

Group type: EXPERIMENTAL
Intervention: Integrated care (IC; n = 65; age mean+/‐sd 70+/‐9 yrs; FEV(1) 1.1+/‐0.5 L, 43% predicted)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual care (UC; n = 90; age 72+/‐9 yrs; FEV(1) 1.1+/‐0.05 L, 41% pred)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Integrated care (IC)
Number of subjects: 155
Study: 14571611

Group type: EXPERIMENTAL
Intervention: Integrative medical treatment (IMT) with serial Chinese recipes and western medicine
Number of subjects: 85

Group type: COMPARATOR
Intervention: Western medicine alone (control group)
Number of subjects: 85
Study: 11028724

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of bupivacaine/fentanyl (EPI group)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional analgesic regimen (intramuscular oxycodone, OPI group)
Number of subjects: 77
Study: 9343116

Group type: EXPERIMENTAL
Intervention: 200 mg tolcapone tid
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 100 mg tolcapone tid
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 8363071

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of 75 micrograms clonidine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3466377

Group type: EXPERIMENTAL
Intervention: Intraligamental anaesthesia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control surfaces (no anaesthesia)
Number of subjects: 26
Study: 29070768

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy for 24 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (pituitary disease without GH deficiency), n=8
Number of subjects: 9
Study: 27181422

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 25563708

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cumulative arrhythmia burden
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Duration of the longest episode of AF
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: AF load
Number of subjects: 96
Study: 23278870

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA) combined with low-fluence 1064-nm QSNY laser treatment for melasma, taken for 8 weeks.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low-fluence 1064-nm QSNY laser treatment for melasma (control group).
Number of subjects: 48
Study: 20977582

Group type: EXPERIMENTAL
Intervention: High-protein meal (860 kJ, 21 g protein, 0.7 g fat, 29.6 g carbohydrate) ingested immediately prior to resistance training (RT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: High-protein meal (860 kJ, 21 g protein, 0.7 g fat, 29.6 g carbohydrate) ingested at least 2 hours following resistance training (RT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups (immediate and delayed protein ingestion)
Number of subjects: 34
Study: 18642658

Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control (2HRZ/4HR chemotherapy)
Number of subjects: 360
Study: 16896999

Group type: EXPERIMENTAL
Intervention: Ramipril therapy (ACE inhibitor)
Number of subjects: 0
Study: 12510038

Group type: EXPERIMENTAL
Intervention: 3 mg of intravenous natalizumab per kilogram
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 6 mg of intravenous natalizumab per kilogram
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 10939785

Group type: EXPERIMENTAL
Intervention: Perindopril (ACE inhibitor) and indapamide (diuretic) for those without contraindications
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Matching placebo(s)
Number of subjects: 6105
Study: 8865870

Group type: EXPERIMENTAL
Intervention: Computerized urea kinetic model (PACK‐PD) for calculating prescription parameters for peritoneal urea clearance (pKpt/V).
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Measurement of delivered Kpt/V (dKpt/V) over one to 24 months.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Frequent measurement and adjustment of pKpt/V as needed.
Number of subjects: 88
Study: 1476285

Group type: EXPERIMENTAL
Intervention: Albumin (PEA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Albumin and low molecular weight hydroxyethylstarch (Elohes) (PEA+E)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both groups pooled together
Number of subjects: 12
Study: 6727656

Group type: EXPERIMENTAL
Intervention: h‐PRL induced by oral priming with 10 mg metoclopramide (MET)
Number of subjects: 8

Group type: COMPARATOR
Intervention: normoprolactinemia (n‐PRL) after oral priming with placebo
Number of subjects: 8
Study: 30876432

Group type: EXPERIMENTAL
Intervention: rIPostC (twice daily exposure to four cycles of 5-min cuff inflation to > 20 mmHg above systolic blood pressure)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham conditioning (twice daily exposure to four cycles of 5-min cuff inflation to 50 mmHg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: rIPostC
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham conditioning
Number of subjects: 200
Study: 30396470

Group type: EXPERIMENTAL
Intervention: Multidisciplinary assessment and decision making process regarding amputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amputation (if decided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No amputation (if decided)
Number of subjects: 0
Study: 27645352

Group type: EXPERIMENTAL
Intervention: GNbAC1 6 mg/kg
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: GNbAC1 12 mg/kg
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: GNbAC1 18 mg/kg
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 25227078

Group type: EXPERIMENTAL
Intervention: EEG neurofeedback (NF) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study: 22855341

Group type: EXPERIMENTAL
Intervention: Mediterranean diet enriched with virgin olive oil (MedDiet+VOO)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Mediterranean diet enriched with nuts (MedDiet+nuts)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Low‐fat control diet
Number of subjects: 127
Study: 20138255

Group type: EXPERIMENTAL
Intervention: D1 receptor antagonist [(11)C]SCH23390
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 40
Study: 17912528

Group type: EXPERIMENTAL
Intervention: Covered urethroplasty (CU group) with a vascularized subcutaneous ventral flap
Number of subjects: 130

Group type: COMPARATOR
Intervention: Non-covered urethroplasty (NCU group)
Number of subjects: 130
Study: 16207776

Group type: EXPERIMENTAL
Intervention: High self-esteem, highly contingent targets under ego threat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low self-esteem, highly contingent targets under ego threat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Partners of high self-esteem targets
Number of subjects: 0
Study: 12021622

Group type: EXPERIMENTAL
Intervention: Topiramate plus AED inducers (Group A)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Topiramate plus AED noninducers (Group B)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Topiramate (both groups)
Number of subjects: 116
Study: 10406047

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Mechanical ventilation (MV) alone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy control infants
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Infants with interstitial lung disease (ILD)
Number of subjects: 22
Study: 7750669

Group type: EXPERIMENTAL
Intervention: 10 mg cisapride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg cisapride
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1412112

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 50 mg every six hours for 48 hours followed by oral prednisone (20 mg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 100 mg every six hours for 48 hours followed by oral prednisone (40 mg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 500 mg every six hours for 48 hours followed by oral prednisone (60 mg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All groups (low, medium, high dose hydrocortisone)
Number of subjects: 66
Study: 3998832

Group type: EXPERIMENTAL
Intervention: Augmented fluid replacement (2800 +/- 400 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine fluid administration (1220 +/- 102 ml)
Number of subjects: 20
Study: 31262657

Group type: EXPERIMENTAL
Intervention: Dose-escalation strategy (starting dose 80 mg/day orally with weekly escalation to 160 mg/day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard-dose strategy (160 mg/day orally for 21 days of a 28-day cycle)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Dose-escalation strategy
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard-dose strategy
Number of subjects: 123
Study: 29635252

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel and aspirin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Major allele G at rs12041331, minor allele G at rs2644592, minor allele C at rs11264580, minor allele C at rs11249454
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minor allele T at rs57731889, minor allele A at rs16863356, minor allele T at rs7634096
Number of subjects: 0
Study: 26728933

Group type: EXPERIMENTAL
Intervention: Trial and Error Learning (TE)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Errorless Learning (EL)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Learning by Modeling with Spaced Retrieval (MR)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: All three learning methods
Number of subjects: 52
Study: 24144654

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study: 22869515

Group type: EXPERIMENTAL
Intervention: Shockwave therapy (SW)
Number of subjects: 22
Study: 20231521

Group type: EXPERIMENTAL
Intervention: Palosuran 125 mg BID for 4 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 54
Study: 19002405

Group type: EXPERIMENTAL
Intervention: Molsidomine (16 mg once daily)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study: 16475602

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 10% CP + 0.05% calcium
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 10% CP + 0.1% calcium
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 10% CP + 0.2% calcium
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 10% CP + 0.2% fluoride
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 10% CP + 0.5% fluoride
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (without bleaching and storage in artificial saliva)
Number of subjects: 98
Study: 12518496

Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste
Number of subjects: 109

Group type: COMPARATOR
Intervention: Crest Gum Care Toothpaste
Number of subjects: 109
Study: 9949387

Group type: EXPERIMENTAL
Intervention: Liposuction combined with Controlled Compression Therapy (CCT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Controlled Compression Therapy (CCT) alone
Number of subjects: 20
Study: 8158702

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy to the breast (XRT group)
Number of subjects: 381

Group type: COMPARATOR
Intervention: No further treatment (non-XRT group)
Number of subjects: 381
Study: 2893864

Group type: COMPARATOR
Intervention: Standard TOPV (1,000,000, 100,000, and 300,000 TCID50 of types 1, 2, and 3)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: New formulation of TOPV (600,000 TCID50 of type 3)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Monovalent vaccine (300,000 TCID50 of type 3)
Number of subjects: 441
Study: 30505457

Group type: EXPERIMENTAL
Intervention: Adapted programme
Number of subjects: 243

Group type: COMPARATOR
Intervention: Standard programme
Number of subjects: 243
Study: 27816804

Group type: EXPERIMENTAL
Intervention: MDCO‐216 (apoA-IMilano/POPC) at doses of 5, 10, 20, 30, or 40 mg/kg infused over 2 hours
Number of subjects: 0
Study: 25896601

Group type: EXPERIMENTAL
Intervention: Two-hand technique
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Left one-hand technique
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Right one-hand technique
Number of subjects: 36
Study: 23690341

Group type: EXPERIMENTAL
Intervention: 500 mL of water
Number of subjects: 22

Group type: COMPARATOR
Intervention: 50 mL of water
Number of subjects: 22
Study: 20533627

Group type: EXPERIMENTAL
Intervention: iBond, Heraeus
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Xeno V, Dentsply
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Gluma desensitizer, Heraeus
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bifluorid 12, Voco
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 31
Study: 18067963

Group type: EXPERIMENTAL
Intervention: 600 IU natural-source vitamin E on alternate days
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study: 17161256

Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg once-daily for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 25
Study: 12687873

Group type: EXPERIMENTAL
Intervention: Initial shock of 14 J
Number of subjects: 720

Group type: COMPARATOR
Intervention: Full output shock energy of 31 J
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 720
Study: 10922144

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 336
Study: 9373422

Group type: EXPERIMENTAL
Intervention: Monitored light intravenous sedation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Unmonitored deep intravenous sedation
Number of subjects: 300
Study: 7514238

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 13000
Study: 3091370

Group type: EXPERIMENTAL
Intervention: Cis-platinum
Number of subjects: 146

Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 146
Study: 30808207

Group type: EXPERIMENTAL
Intervention: Supportive care program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsupported group
Number of subjects: 0
Study: 28954299

Group type: EXPERIMENTAL
Intervention: Three doses of HPV16/18 vaccine
Number of subjects: 2439

Group type: EXPERIMENTAL
Intervention: Two doses of HPV16/18 vaccine (0/6 months)
Number of subjects: 2439

Group type: EXPERIMENTAL
Intervention: Two doses of HPV16/18 vaccine (0/1 month)
Number of subjects: 2439

Group type: EXPERIMENTAL
Intervention: One dose of HPV16/18 vaccine
Number of subjects: 2439

Group type: COMPARATOR
Intervention: Unvaccinated control group (UCG)
Number of subjects: 2439
Study: 27168167

Group type: EXPERIMENTAL
Intervention: Intramuscular hydroxyprogesterone caproate (250 mg weekly)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Vaginal progesterone suppository (100 mg daily)
Number of subjects: 145